• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Journey Medical And 2 Other Stocks Under $4 Insiders Are Buying

    3/28/24 7:14:55 AM ET
    $CIA
    $DERM
    $RVP
    Life Insurance
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CIA alert in real time by email

    The Dow Jones index closed higher by over 475 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Retractable Technologies

    • The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw acquired a total of 5,096 shares an average price of $1.18. To acquire these shares, it cost around $6,024.
    • What’s Happening: On Nov. 14, Retractable Technologies reported that its loss from operations was $8.7 million for the first nine months of 2023.
    • What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.

    Citizens

    • The Trade: Citizens, Inc. (NYSE:CIA) Director James Keith Morgan acquired a total of 5,899 shares at at an average price of $2.11. To acquire these shares, it cost around $12,469.
    • What’s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens.
    • What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.

    Check This Out: Walgreens Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

    Journey Medical

    • The Trade: Journey Medical Corporation (NASDAQ:DERM) Director Lindsay A MD Rosenwald acquired a total of 10,000 shares at an average price of $3.04. The insider spent around $30,400 to buy those shares.
    • What’s Happening: On March 21, Journey Medical posted a profit for the fourth quarter.
    • What Journey Medical Does: Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions.

     

    Don’t forget to check out our premarket coverage here

    Get the next $CIA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CIA
    $DERM
    $RVP

    CompanyDatePrice TargetRatingAnalyst
    Journey Medical Corporation
    $DERM
    8/25/2025$13.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    7/30/2025$12.00Buy
    B. Riley Securities
    Journey Medical Corporation
    $DERM
    8/22/2024$9.00Buy
    Rodman & Renshaw
    Journey Medical Corporation
    $DERM
    6/28/2024$11.00Buy
    ROTH MKM
    Journey Medical Corporation
    $DERM
    2/25/2022$9.00Overweight
    Cantor Fitzgerald
    Journey Medical Corporation
    $DERM
    12/16/2021$15.00Buy
    Roth Capital
    Journey Medical Corporation
    $DERM
    12/7/2021$14.00Buy
    B. Riley Securities
    Citizens Inc.
    $CIA
    7/19/2021$6.70 → $8.40Neutral → Buy
    Goldman Sachs
    More analyst ratings

    $CIA
    $DERM
    $RVP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Journey Medical with a new price target

    H.C. Wainwright initiated coverage of Journey Medical with a rating of Buy and set a new price target of $13.00

    8/25/25 8:12:40 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities resumed coverage on Journey Medical with a new price target

    B. Riley Securities resumed coverage of Journey Medical with a rating of Buy and set a new price target of $12.00

    7/30/25 8:21:38 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Journey Medical with a new price target

    Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00

    8/22/24 7:21:37 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $DERM
    $RVP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Shaw Thomas J bought $4,424 worth of shares (5,731 units at $0.77), increasing direct ownership by 0.04% to 15,831,222 units (SEC Form 4)

    4 - RETRACTABLE TECHNOLOGIES INC (0000946563) (Issuer)

    11/17/25 11:29:38 AM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Shaw Thomas J bought $81 worth of shares (100 units at $0.81), increasing direct ownership by 0.00% to 15,825,491 units (SEC Form 4)

    4 - RETRACTABLE TECHNOLOGIES INC (0000946563) (Issuer)

    11/13/25 1:29:23 PM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Shaw Thomas J bought $6,195 worth of shares (7,500 units at $0.83), increasing direct ownership by 0.05% to 15,825,391 units (SEC Form 4)

    4 - RETRACTABLE TECHNOLOGIES INC (0000946563) (Issuer)

    11/6/25 10:53:09 AM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    $CIA
    $DERM
    $RVP
    SEC Filings

    View All

    SEC Form 10-K filed by Citizens Inc.

    10-K - CITIZENS, INC. (0000024090) (Filer)

    3/12/26 4:11:09 PM ET
    $CIA
    Life Insurance
    Finance

    Citizens Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - CITIZENS, INC. (0000024090) (Filer)

    3/12/26 4:09:19 PM ET
    $CIA
    Life Insurance
    Finance

    Citizens Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CITIZENS, INC. (0000024090) (Filer)

    3/10/26 11:13:16 AM ET
    $CIA
    Life Insurance
    Finance

    $CIA
    $DERM
    $RVP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Hoxworth Seth Alan claimed ownership of 5,352 units of Citizens (SEC Form 3)

    3 - CITIZENS, INC. (0000024090) (Issuer)

    3/16/26 5:35:07 PM ET
    $CIA
    Life Insurance
    Finance

    Taylor Mary increased direct ownership by 1% to 48,364 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:29:36 AM ET
    $CIA
    Life Insurance
    Finance

    Davis Cynthia H increased direct ownership by 0.93% to 45,967 units (SEC Form 5)

    5 - CITIZENS, INC. (0000024090) (Issuer)

    1/30/26 10:28:28 AM ET
    $CIA
    Life Insurance
    Finance

    $CIA
    $DERM
    $RVP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

    Retractable Technologies, Inc. ("Retractable") (NYSE:RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning October 1, 2025 through December 31, 2025. The dividends will be paid on January 20, 2026 to shareholders of record as of the close of business on January 10, 2026. Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and

    12/30/25 4:14:00 PM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

    Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administrat

    12/10/25 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream

    MIAMI, Dec. 10, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 88th Emerging Growth Conference on December 10 & 11, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Presenting Day 1 – Today - December 10, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already regis

    12/10/25 7:00:00 AM ET
    $AEM
    $CIA
    $CLNN
    Precious Metals
    Basic Materials
    Life Insurance
    Finance

    $CIA
    $DERM
    $RVP
    Financials

    Live finance-specific insights

    View All

    Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

    Retractable Technologies, Inc. ("Retractable") (NYSE:RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning October 1, 2025 through December 31, 2025. The dividends will be paid on January 20, 2026 to shareholders of record as of the close of business on January 10, 2026. Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and

    12/30/25 4:14:00 PM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quar

    11/12/25 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

    SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2025 financial results after the U.S. financial markets close on Wednesday, November 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the

    11/5/25 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $DERM
    $RVP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Retractable Technologies Inc. (Amendment)

    SC 13G/A - RETRACTABLE TECHNOLOGIES INC (0000946563) (Subject)

    2/8/23 2:38:31 PM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Journey Medical Corporation (Amendment)

    SC 13G/A - Journey Medical Corp (0001867066) (Subject)

    12/29/22 5:15:07 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CIA
    $DERM
    $RVP
    Leadership Updates

    Live Leadership Updates

    View All

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

    SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

    4/1/25 4:01:16 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

    SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

    7/11/24 4:05:39 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care